CELLULOSE NANOFIBRILLAR BIOINK FOR 3D BIOPRINTING FOR CELL CULTURING, TISSUE ENGINEERING AND REGENERATIVE MEDICINE APPLICATIONS
원문보기
IPC분류정보
국가/구분
United States(US) Patent
공개
국제특허분류(IPC7판)
A61L-027/20
C09D-011/14
B33Y-070/00
A61L-027/38
B33Y-080/00
C09D-011/04
B29L-031/00
A61F-002/04
B29C-064/112
B29K-001/00
출원번호
US-0537154
(2015-12-18)
공개번호
US-0368225
(2017-12-28)
국제출원번호
PCT/US15/66755
(2015-12-18)
발명자
/ 주소
Gatenholm, Paul
출원인 / 주소
CELLINK AB
인용정보
피인용 횟수 :
0인용 특허 :
0
초록▼
The present invention relates to biomaterial in the form of dispersion of cellulose nanofibrils with extraordinary shear thinning properties which can be converted into desire 3D shape using 3D Bioprinting technology. In this invention cellulose nanofibril dispersion, is processed through different
The present invention relates to biomaterial in the form of dispersion of cellulose nanofibrils with extraordinary shear thinning properties which can be converted into desire 3D shape using 3D Bioprinting technology. In this invention cellulose nanofibril dispersion, is processed through different mechanical, enzymatic and chemical steps to yield dispersion with desired morphological and rheological properties to be used as bioink in 3D Bioprinter. The processes are followed by purification, adjusting of osmolarity of the material and sterilization to yield biomaterial which has cytocompatibility and can be combined with living cells. Cellulose nanofibrils can be produced by microbial process but can also be isolated from plant secondary or primary cell wall, animals such as tunicates, algae and fungi. The present invention describes applications of this novel cellulose nanofibrillar bioink for 3D Bioprinting of tissue and organs with desired architecture.
대표청구항▼
1-30. (canceled) 31. A cellulose nanofibril bioink comprising: a dispersion of cellulose nanofibrils in a liquid media, wherein the cellulose nanofibrils have a length of about 1-100 microns and a width of about 10-30 nanometers;a viscosity of between 1 and 50 Pa·s at 100 s−1;a solids content rangin
1-30. (canceled) 31. A cellulose nanofibril bioink comprising: a dispersion of cellulose nanofibrils in a liquid media, wherein the cellulose nanofibrils have a length of about 1-100 microns and a width of about 10-30 nanometers;a viscosity of between 1 and 50 Pa·s at 100 s−1;a solids content ranging from about 1-3%. 32. The cellulose nanofibril bioink of claim 31, wherein the cellulose nanofibrils have an average length of about 1-10 microns and an average width of about 10-20 microns. 33. The cellulose nanofibril bioink of claim 31 comprising one or more biopolymers chosen from collagen or elastin. 34. A method comprising: providing a cellulose nanofibril bioink comprising: a dispersion of cellulose nanofibrils in a liquid media, wherein the cellulose nanofibrils have a length of about 1-100 microns and a width of about 10-30 nanometers;a viscosity of between 1 and 50 Pa·s at 100 s−1; anda solids content ranging from about 1-3%; andbioprinting a 3D construct with the cellulose nanofibril bioink as a support. 35. The method of claim 34, wherein the 3D bioprinting comprises 3D bioprinting of scaffolds, tissues, and/or organs. 36-37. (canceled) 38. The method of claim 34, wherein the 3D bioprinting comprises 3D bioprinting with cells. 39. The method of claim 34, wherein the 3D bioprinting comprises 3D bioprinting without cells. 40. The method of claim 38, wherein the cells are human cells. 41. (canceled) 42. A method of reinforcing a tissue or an organ of a human or animal, the method comprising: (a) obtaining a cellulose-based bioink prepared by a method comprising:processing cellulose nanofibrillar material using mechanical, enzymatic and/or chemical processing steps to yield a cellulose nanofibrillar dispersion;purifying the cellulose nanofibrillar dispersion; andsterilizing the cellulose nanofibrillar dispersion to yield the cellulose-based bioink;(b) 3D printing a 3D bioprinted material using the cellulose-based bioink;(c) reinforcing the tissue or organ with the 3D bioprinted material. 43. The method of claim 42, wherein the reinforcing is performed by implanting the 3D bioprinted material into the human or animal. 44. The method of claim 42, which is a method of plastic surgery. 45. The method of claim 42, which is a method of repairing defects of hyaline cartilage, defects of cartilage tissue, defects of connective tissue, defects of cardiovascular tissue, osteochondral defects, or defects of breast tissue. 46. The method of claim 45, wherein the cartilage tissue is cartilage tissue of a nose, ear, meniscus, or trachea. 47. The method of claim 45, wherein the connective tissue is skin. 48. A method of providing an organ to a human or animal in need thereof, the method comprising: (a) obtaining a cellulose-based bioink prepared by a method comprising:processing cellulose nanofibrillar material using mechanical, enzymatic and/or chemical processing steps to yield a cellulose nanofibrillar dispersion;purifying the cellulose nanofibrillar dispersion; andsterilizing the cellulose nanofibrillar dispersion to yield the cellulose-based bioink;(b) 3D printing a 3D bioprinted organ using the cellulose-based bioink;(c) implanting the 3D bioprinted organ into the human or animal. 49-57. (canceled) 58. The method of claim 34, further comprising reinforcing a tissue or organ with the 3D construct. 59. The method of claim 58, wherein the tissue or organ is a human or animal tissue or organ. 60. The method of claim 34, wherein the 3D construct is an organ. 61. The method of claim 60, further comprising implanting the organ into a human or animal.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.